Full text is available at the source.
Abstract
Semaglutide 2.4mg has shown a reduction in cardiovascular mortality and non-fatal cardiovascular events.
- Obesity is linked to higher cardiovascular risk.
- Drugs like liraglutide, semaglutide, and tirzepatide may improve weight, body composition, and glucose metabolism.
- Semaglutide 2.4mg is associated with reduced symptoms of heart failure.
- Tirzepatide may also reduce cardiovascular mortality and heart failure symptoms in obese patients.
- These glucagon-like peptide-1 receptor agonists represent a significant advancement in obesity treatment.
Simplified